Nutriband Inc. Pioneers Abuse-Deterrent Technology in Response to Opioid Crisis

Nutriband Inc. (NASDAQ: NTRB) is making strides in the pharmaceutical industry with its innovative Aversa(TM) technology, aimed at preventing the abuse and misuse of transdermal drug delivery systems, particularly for potent opioids such as fentanyl. The development of abuse-deterrent technologies is a critical response to the ongoing opioid crisis, which has highlighted the dangers of drug diversion and misuse. Fentanyl, known to be 50 times more potent than heroin, poses significant risks even in trace amounts, making the need for safer delivery systems more urgent than ever.

The Aversa(TM) fentanyl patch, currently under development by Nutriband, represents a significant advancement in this field. With an estimated market potential of $80 million to $200 million annually within five years of launch, the technology not only addresses a pressing public health issue but also offers substantial economic opportunities. By integrating abuse-deterrent features into transdermal patches, Nutriband is tackling the dual challenge of ensuring patient access to necessary medications while minimizing the risk of misuse.

For investors and stakeholders interested in following Nutriband's progress, the company's latest updates are available in its newsroom at https://ibn.fm/NTRB. This initiative underscores Nutriband's commitment to innovation in drug delivery, positioning the company as a leader in the development of technologies that safeguard against the abuse of controlled substances.